Commonly used regimens in cancer therapy rely on the induction of apoptotic cell death, and drug resistance can be attributed, at least in part, to a disabled apoptotic program. Non-small cell lung carcinomas (NSCLC), exhibit an intrinsic resistance to chemotherapy. Here, we show that co-treatment with etoposide (VP16) and the pan-histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not valproic acid (VPA), induced apoptotic cell death in drug-resistant NSCLC cells. Co-treatment, but not single treatment, with VP16 and TSA induced apoptosis in a caspase-dependent manner accompanied by a crucial decrease in Bcl-xL expression allowing Bax activation and subsequent initiation of the apoptosis inducing factor (AIF)-dependent death pathway. Importantly, AIF proved to be required for the effects of TSA/ VP16 as RNA knockdown of AIF resulted in a complete abolishment of TSA/VP16-induced apoptotic cell death in drug-resistant NSCLC cells. Our results thus provide evidence for the requirement of both caspase-dependent and caspase-independent apoptotic pathways in TSA/ VP16-mediated death of drug-resistant NSCLC cells, and extend previous suggestions that HDAC inhibitors in combination with conventional chemotherapeutic drugs could be valuable in the treatment of NSCLC cancer and other malignancies in which Bcl-xL is overexpressed.
Introduction
Apoptosis plays a central role in the elimination of potentially dangerous cells including the precursors of tumor cells. Most currently used antitumor agents, including chemotherapeutic drugs and g-irradiation, kill cancer cells by stimulating the apoptotic machinery, and therapy resistance can be attributed, at least in part, to a disabled apoptotic program (Zhivotovsky et al., 1999) . Non-small cell lung carcinomas (NSCLC) exhibit an intrinsic resistance to chemo-and radiotherapy (Joseph et al., 2001) .
We previously demonstrated that at least two apoptotic pathways coexist in NSCLC. The first one operates via the release of cytochrome c (Cyt c) and activation of caspases. The second one acts via induction of mitochondrial dysfunction followed by the redistribution of the apoptosis inducing factor (AIF) from the mitochondria into the nucleus. The resistance to conventional cytotoxic drugs and ionizing radiation treatment of NSCLC cells is coupled both to the absence of initiation of the AIF-dependent pathway and to a block in the Cyt c/caspase-dependent pathway due to an absence of translocation of active caspase-3 to the nucleus (Joseph et al., 2001 (Joseph et al., , 2002 Gallego et al., 2004) . This defective translocation is accompanied by the absence of nuclear hallmarks of apoptosis such as cleavage of poly(ADP-ribose)polymerase (PARP), as well as DNA fragmentation. The possibility of reactivation of the apoptotic execution machinery in NSCLC cells, resistant to conventional anticancer treatment is therefore of interest.
Growing experimental evidence suggests that neoplastic transformation, characterized by altered patterns of cell death, does not necessarily destroy the potential that cells have to undergo apoptosis under appropriate environmental conditions. Various chemical agents can restore this potential in transformed cells, and these possibilities are currently being exploited in attempts to develop anticancer therapies using such agents. Among the most effective of these are histone deacetylase (HDAC) inhibitors (Henderson and Brancolini, 2003) . Histone acetylation and deacetylation play important roles in the modulation of chromatin topology and the regulation of gene transcription. HDAC inhibition induces the accumulation of hyperacetylated nucleosome core histones in most regions of chromatin but affects the expression of only a small subset of genes, leading to transcriptional activation of some genes, but repression of an equal or larger number of other genes (Marks and Jiang, 2005; Peart et al., 2005) . HDAC inhibitors (HDACis) comprise a diverse range of unrelated compounds that all induce an accumulation of hyperacetylated histones resulting in various biological effects (for example, cell cycle arrest, cell death or differentiation) (Minucci and Pelicci, 2006) . These outcomes are to a large extent cell-type specific and have raised the potential that the HDACis may represent a promising new class of antineoplastic agents. The present study was designed to investigate, in the model of chemoresistance represented by NSCLC cells, the effect of HDACs inhibition on activation and/or efficiency of the different apoptotic signaling pathways.
Results
Co-treatment with etoposide and the pan-HDACi TSA induces cell death in NSCLC cells NSCLC cells, including H157 cells, have previously been shown to be resistant to apoptosis induced by DNAdamaging agents such as etoposide (VP16) (Joseph et al., 2001) . First, the HDAC inhibitory activities of both valproic acid (VPA) and trichostatin A (TSA) was confirmed in H157 cells by immunodetection of acetylated histone H4 (Supplementary Figure S1) . Then, we investigated by fluorescence-activated cell sorting (FACS) analysis whether cell death can be observed upon chemical inhibition of HDACs alone or in combination with VP16 treatment. NSCLC cells sensed DNA damage induced by VP16 and were arrested in G 2 /M. However, this cell cycle arrest was not followed by manifestation of hypoploidy (Joseph et al., 2001) (Figure 1a) . Treatment of H157 cells with 1 mM VPA, a concentration, which has been shown to preferentially target class I HDAC (Gottlicher et al., 2001) , had no effect on cell death. In addition at this dose, VPA in association with VP16 had only minor consequence on cell survival. On the other hand, the pan-HDACi TSA at low concentrations (20ng ml À1 ) was able to revert the resistance of H157 cells to VP16 treatment. Indeed, whereas neither VP16 nor TSA treatment alone did promote cell death, their association resulted in substantial apoptosis in H157 cells as documented by the appearance of a sub-G 1 peak (Figure 1a) . The killing effects of the combined treatment with TSA/VP16 were also observed in H23 and H1299 NSCLC cell lines (data not shown).
TSA/VP16 co-treatment restores the caspase-dependent apoptotic pathways in H157 NSCLC cells NSCLC cells are resistant to VP16-induced apoptosis even though mitochondrial release of Cyt c and activation of caspase-3 are detectable (Figures 1b and c) (Joseph et al., 2001) . In fact, the resistance to conventional cytotoxic drugs and ionizing radiation treatment of NSCLC cells seems to be coupled to an Figure 1 The Cyt c/caspase-dependent apoptotic pathway is induced upon TSA/VP16 co-treatment and competently triggers PARP cleavage in H157 cells. H157 cells were treated with VPA (1 mM; preferentially inhibiting class I HDACs), or the pan-HDACi TSA (20 ng ml
À1
) alone or in association with VP16 (5 mM) for 12 (b), 24 (c and d) or 48 h (a). (a) Appearance of subdiploid-fragmented nuclei derived from apoptotic cells was analysed by FACS after DNA staining with propidium iodide. Percentages depicted stand for the fraction of the cell population in sub-G 1 . Data shown are representative of multiple independent experiments. Bars and error bars represent mean with s.e.m. (b) Cytosol cell extracts were prepared and subjected to immunoblotting with anti-Cyt c antibodies. Actin was used as standard for equal loading of protein. (c) Caspase-3-like activity was determined by the cleavage of the specific peptide substrate DEVD-AMC. The maximum linear rate of AMC release was estimated by linear regression. Data shown are the average of three independent experiments performed in duplicate. Bars and error bars represent mean with s.e.m. (d) Total protein cell extracts were analysed by immunoblotting for the presence of 116 kDa native PARP and its 89 kDa caspase-3-cleavage product. G3PDH was used as protein loading control.
TSA/VP16 induces apoptosis in NSCLC cells N Hajji et al absence of translocation of active caspase-3 to the nucleus, which is accompanied by the absence of nuclear signs of apoptosis such as PARP cleavage (Figure 1d ) (Joseph et al., 2001; Gallego et al., 2004) . We analysed Cyt c release into the cytosol, activation of caspase-3 and processing of PARP to determine if the TSA/ VP16-induced cell death in NSCLC cells depended upon the restoration of the Cyt c/caspase-dependent pathway of apoptosis. The presence of Cyt c was detected by immunoblotting in cytosolic extracts from VP16-treated H157 cells. Co-treatment with VPA/VP16 or TSA/VP16 resulted in an improved Cyt c release in those cells as compared to single VP16 exposure (Figure 1b ). Caspase-3 activity was detected after VP16 treatment of H157 cells. This activity was enhanced when cells were co-treated with each one of the HDACi tested ( Figure 1c ). Since VP16-treated NSCLC cells do not show nuclear apoptosis despite mitochondrial release of Cyt c and activation of caspase-3, we decided to examine whether cleavage of PARP occurs in H157 cells undergoing apoptosis upon TSA/VP16 co-treatment. Indeed, the cleavage of the nuclear protein PARP was observed by immunoblotting upon TSA/VP16 co-treatment ( Figure 1d ). In addition, confocal imaging analysis confirmed the effective translocation of the active caspase-3 to the nucleus upon exposure to VP16 and TSA (data not shown). Thus, TSA/VP16 co-treatment restored the Cyt c/caspase-dependent cell death pathway in NSCLC cells, as documented by the appearance of nuclear hallmarks of apoptosis, for example, PARP processing and hypoploidy.
TSA/VP16 co-treatment activates the AIF-dependent apoptotic pathways in H157 NSCLC cells We previously reported that NSCLC cell lines are sensitive to the action of staurosporine (STS) despite deficiencies in the Cyt c/caspase-dependent arm of the lethal signal transduction. In contrast to treatment with g-irradiation or VP16, STS induced both caspase activation and mitochondrial dysfunction associated with AIF release in NSCLC cells, suggesting that AIF plays a major role in the death of NSCLC cells (Joseph et al., 2002; Gallego et al., 2004) . Whereas the release of Cyt c from mitochondria to cytosol does not require a mitochondrial transmembrane depolarization (Martinou and Green, 2001) , the release of AIF from the mitochondrion has been shown to be dependent on the opening of mitochondrial permeability transition pores (Zamzami and Kroemer, 2001; Joseph et al., 2002) . To further characterize TSA/VP16-killing ability, we evaluated the putative involvement of the AIF-dependent apoptotic pathway. The loss of mitochondrial transmembrane potential (DCm), the mitochondrion-nuclear translocation of AIF and large-scale DNA fragmentation were investigated. As shown in Figure 2a , VP16 induced hyperpolarization of DCm measured by an increase of the uptake of the potential-sensitive dye tetramethylrhodamine ethyl ester (TMRE) (Pham and Hedley, 2001) . However, it is noteworthy that this hyperpolarization was not followed by any drop of DCm as observed up to 48 h (data not shown). Interestingly, only upon the combined exposure to VP16 and TSA, a depolarization of DCm was observed in H157 cells, as illustrated by the reduction of TMRE uptake. Next, the subcellular localization of AIF in H157 cells was investigated by confocal microscopy. Using antibodies against AIF, punctate cytoplasmic staining pattern with some preference for the perinuclear area was yielded, as shown by simultaneous DAPI staining of the nuclei (Figure 2b ). This profile of staining is typical for mitochondrial localization of proteins. Five hours after TSA/VP16, combined treatment mitochondrial release of AIF was observed, as documented by the loss of punctate cytoplasmic staining and appearance of more diffuse distribution of AIF in H157 cells. As mentioned above, AIF is not located in the nucleus in untreated cells. However, after TSA/VP16 co-treatment a large portion of AIF was found within the nucleus, at the same time when 4,6-diamidino-2-phenylindole (DAPI)-detectable chromatin condensation became apparent (Figures 2b and 4b ). In addition, H157 cells also developed large-scale DNA fragmentation after TSA/VP16 exposure, which confirmed the nuclear translocation of AIF ( Figure 2c ). These data demonstrated that the combined treatment with the panHDACi TSA and the DNA damaging agent VP16 is able to induce apoptosis in NSCLC. These data also suggested that both the Cyt c/caspase-dependent and the AIF-dependent pathways of cell death were activated by this combined treatment.
The pan-caspase inhibitor zVAD-fmk inhibits TSA/ VP16-induced apoptosis in H157 NSCLC cells To understand the implication of caspases in the mechanism of TSA/VP16-induced killing of NSCLC cells, the effect of zVAD-fmk, a pan-caspase inhibitor, was investigated. Incubation of lung cancer cells with zVAD-fmk did not influence their survival (data not shown). Preincubation for 1 h with 20 mM zVAD-fmk completely inhibited caspase-3 activity in H157 cells treated with VP16 alone or in association with TSA ( Figure 3a ). In accordance, preincubation with the caspase inhibitor resulted in a marked inhibition of PARP processing in TSA/VP16-treated H157 cells ( Figure 3b ). Importantly, it also appeared that zVADfmk treatment abolished TSA/VP16-induced cell death, as demonstrated by the reduction of the hypoploidic fraction observed by FACS analysis and decrease in the number of condensed or fragmented nuclei detected upon DAPI staining, suggesting that the TSA/VP16-induced cell death is caspase-dependent ( Figure 3c and data not shown). Then we investigated whether zVAD-fmk might also hinder the drop of DCm, the subsequent release of mitochondrial AIF and the resulting large-scale DNA fragmentation and therefore abolish TSA/VP16-induced cell death. One-hour preincubation of cells with zVADfmk resulted in a marked inhibition of the decrease of TMRE uptake observed in TSA/VP16-treated H157 cells ( Figure 4a ). In addition, analysis of AIF subcellular localization by confocal microscopy revealed that H157 TSA/VP16 induces apoptosis in NSCLC cells N Hajji et al cells pretreated with zVAD-fmk and then co-treated with TSA/VP16 retained the staining profile typical for mitochondrial localization of proteins (Figures 2b and 4b) . In agreement with the observed inhibition of AIF release, zVAD-fmk drastically suppressed the large-scale DNA fragmentation observed after incubation with TSA/VP16 ( Figure 4c ). These pharmacological experiments with the broad spectrum inhibitor of caspases, zVAD-fmk, revealed that caspase activation is required not only for the processing of nuclear proteins such as PARP, but also for the release of AIF from mitochondria. Activated caspase-8 can amplify the apoptotic signal by cleaving Bid, a BH3 domain-containing pro-apoptotic Bcl-2 family member (Kruidering and Evan, 2000) . Once Bid is cleaved by caspase-8, Bid is able to activate Bax and induce mitochondrial damages (Roucou et al., 2002) . Caspase-8 processing/activation was observed in TSA/ VP16-treated H157 cells. Furthermore, TSA/VP16 induced a time-dependent disappearance of full-length Bid protein. Notably, pretreatment with the caspase inhibitor prevented processing of both procaspase-8 and Bid (Figure 4d ). In summary, these data confirm that the TSA/VP16-triggered release of AIF occurs in a caspasedependent fashion.
Knockdown of AIF by siRNA compromises TSA/ VP16-induced apoptosis in H157 NSCLC cells To substantiate the implication of AIF in TSA/VP16-induced apoptosis of NSCLC cells, the effect of gene silencing of AIF with small interference RNA (siRNA) was investigated. For this purpose, H157 cells were co-transfected with green fluorescent protein (GFP) expression vector together with an siRNA designed to interfere with the expression of human AIF or a control siRNA directed against cyan fluorescent protein (CFP), and then treated or not with VP16, TSA or both. Transfection efficiency was estimated to 40-50%. siRNA Figure S2 ), observed upon TSA/VP16 co-treatment in NSCLC cells. These data provide evidence that depletion of AIF results in resistance to apoptosis as the model implies and that AIF is of importance for the efficiency of the death program elicited by the combined TSA/VP16 treatment. Altogether these data established that even if TSA/VP16-induced apoptosis acts in a caspase-dependent manner, the AIF-dependent mitochondrial apoptotic pathway was required for apoptosis to occur in H157 cells.
TSA/VP16 co-treatment results in a crucial decrease in Bcl-xL expression and promotes Bax activation in H157 NSCLC cells Mitochondrial outer-membrane permeabilization, which regulates AIF release, is controlled by pro-and anti-apoptotic members of the Bcl-2 family. The anti-apoptotic family members Bcl-2 and Bcl-xL have been shown to block release of apoptosis-promoting proteins from the mitochondrial intermembrane space, whereas pro-apoptotic members such as Bax promote it (Desagher and Martinou, 2000) . Therefore, we considered possible modulation of the gene expression/activation of pro-and anti-apoptotic members of the Bcl-2 family upon chemical inhibition of HDACs. Regulation of Bax activity involves conformational changes, translocation to mitochondria and oligomerization of Bax (Hsu and Youle, 1998) . Bax activation was investigated by confocal microscopy using antibodies against the active form of this protein. Exposure to VP16 was not able to promote Bax activation in NSCLC cells (Figure 6a ). However, Bax activation and relocalization to the mitochondria were clearly observed in TSA/VP16 co-treated cells. zVAD-fmk significantly repressed Bax activation suggesting that this activation occurs downstream of caspase activation in TSA/VP16-treated NSCLC cells. Second, since HDACis have been reported to modulate the expression of several antiapoptotic members of the Bcl-2 family (Peart et al., 2005) , we analysed the expression of Bcl-2 and Bcl-xL by immunoblotting. Results in Figure 6b show that both HDACis significantly reduced the level of Bcl-2 protein.
As VPA was not able in combination with VP16 to induce cell death in NSCLC cells, this result suggested that Bcl-2 downregulation on its own was not able to sensitize these cells to the VP16-killing effect. Exposure 
TSA/VP16 induces apoptosis in NSCLC cells
N Hajji et al of H157 cells to VP16 led to an increase in the expression of the anti-apoptotic protein Bcl-xL. Interestingly, whereas VPA/VP16 co-treatment did not reduce Bcl-xL expression level compared to VP16-treated cells, TSA/VP16 co-treatment led to a decreased expression of Bcl-xL protein levels, suggesting that this co-treatment specifically inhibited the expression of this anti-apoptotic protein in H157 cells. To confirm that Bcl-xL is an important molecular target for the sensitization of NSCLC cells to apoptotic cell death, the effect of gene silencing of Bcl-xL with siRNA was investigated. siRNA-mediated knockdown of Bcl-xL was able to per se provoke cell death and also to promote VP16-induced apoptosis (Supplementary Figure S3) . These results strengthen the suggestion that TSA/VP16 downregulation of Bcl-xL is essential for the reactivation of the apoptotic programs and, together with other reports, emphasizes a crucial role of Bcl-xL in the resistance of NSCLC cells to apoptosis (Zangemeister-Wittke et al., 2000; Lei et al., 2007) . The downregulation of Bcl-xL upon TSA/VP16 co-treatment appeared to be independent of caspases activation as it was not prevented by zVAD-fmk (Figure 6c) . Real-time quantitative PCR analysis confirmed the downregulation of Bcl-xL at mRNA level by TSA/VP16 (data not shown). Cell death in response to stimuli that require the activation of Bax to induce mitochondrial membrane permeabilization is thought to be prevented upstream of Bax activation by the overexpression of Bcl-xL (Letai et al., 2002) . Hence, we decided to investigate whether increased levels of Bcl-xL could block TSA/VP16 pro-apoptotic effects (Figures  6d and e) . For this purpose, H157 cells were transfected with Bcl-xL expression vector, and then treated or not with VP16, TSA or both. As shown in Figure 6e , ectopic expression of Bcl-xL inhibited Bax conformational Figure 4 zVAD-fmk inhibits mitochondrial transmembrane potential (DCm) loss, release of mitochondrial AIF and large-scale DNA fragmentation in TSA/VP16-treated H157 cells. H157 cells were pretreated with zVAD-fmk for 1 h, prior to treatment with VP16, VPA, TSA alone or in combination for 24 h. (a) Cells were harvested and DCm was assessed by FACS using TMRE staining. (b) Confocal analysis of AIF subcellular localization was carried out as described in Figure 3b . Quantification of signals measured by confocal microscopy (right panel). The fluorescence intensities of cells (AIF staining: red line; DAPI: blue line) were measured along the cursor (white line, left panel) by confocal microscopy as described in the 'Materials and methods'. Data are shown on a linear scale of arbitrary units of fluorescence intensity. This experiment was repeated three times with similar results. (c) Formation of highmolecular weight DNA fragments was determined by using PFGE, as described in the 'Materials and methods'. H157 cells were treated with VP16, TSA or in combination for 24 h. (d) Total protein cell extracts were analysed by immunoblotting for the processing of procaspase-8 and Bid. G3PDH and actin were used as protein loading control.
TSA/VP16 induces apoptosis in NSCLC cells N Hajji et al modification/activation in NSCLC cells. Furthermore, Bcl-xL overexpression was able to inhibit nuclear signs of apoptosis, such as PARP cleavage, observed after TSA/VP16 co-treatment in H157 cells (compare Figure 6d ). Thus, an increased level of Bcl-xL seems to counteract the positive effect of the co-treatment of TSA and VP16 on Bax activation, and consequently inhibit the mitochondrial cell death pathway activated upon Bax conformational changes in TSA/VP16-treated NSCLC cells. Altogether, these data established that the AIF-dependent mitochondrial apoptotic pathway activated upon caspase-dependent activation of Bax is required for TSA/VP16-induced apoptosis to occur in NSCLC cells. Discussion NSCLC, which constitutes over 80% of all newly diagnosed bronchogenic carcinomas, are extremely resistant to conventional anticancer treatment and new approaches are needed to improve the effectiveness of the therapies. In NSCLC cells, the Cyt c/caspasedependent leg of the apoptotic signaling pathways, induced upon ionizing radiation and conventional anticancer drugs such as VP16, appears to be heavily compromised (Joseph et al., 2001) . In addition, the AIFdependent killing pathway appears to play a major role in the death of NSCLC (Joseph et al., 2002; Gallego et al., 2004; Schniewind et al., 2006) . Indeed, NSCLC cell lines are sensitive to the action of the broad protein kinase inhibitor STS, which in addition to the activation of the Cyt c/caspase-dependent apoptotic pathway induces the mitochondrial release of AIF (Joseph et al., 2002) . However, because of high toxicity, STS cannot be used for the treatment of patients. Agents that can remove the inhibition of the cell death pathway(s) may help to increase the sensitivity of NSCLC cells to conventional anticancer treatment.
The inactivation of tumor suppressor genes is an important event in tumorigenesis. These genes can be inactivated not only by deletion or mutation, but also by epigenetic changes including histone modifications (Minucci and Pelicci, 2006) . HDACs regulate the acetylation status of histones at prominent N-terminal lysine residues, and their inhibitors have recently inspired great interest in the cancer research community as a new therapeutic opportunity for hematologic and solid tumors (Marks et al., 2001; La Thangue, 2004; Villar-Garea and Esteller, 2004; Drummond et al., 2005; Marks and Jiang, 2005) . Although HDACis are emerging as a promising new treatment strategy in malignancy, it remains elusive how different HDACis modulate the response to different conventional chemotherapies and how they exert their effect on human NSCLC cells. Indeed, whereas several studies indicate that a range of HDACis can provoke apoptotic cell death in NSCLC cells, other reports revealed that they are ineffective in inducing apoptosis (Yu et al., 2002; Choi, 2005; Rundall et al., 2005; Geng et al., 2006; Komatsu et al., 2006; Schniewind et al., 2006; Witta et al., 2006) . It should be noted that even if all HDACis induce an accumulation of hyperacetylated histones, these are a range of unrelated compounds with unique features and their use can therefore result in various cell-type-specific biological effects. Hence, the combinatorial use of HDACis with different characteristics (Gottlicher et al., 2001 ) is particularly attractive since it potentially can reveal differences in the cellular responses to the drugs which guide us to postulate hypotheses for further investigations of functions for individual HDACs. We found that TSA inhibiting both classes I and II HDACs in combination with VP16 was effective in killing NSCLC cells, whereas the combined treatment VP16 with VPA at concentrations preferentially targeting class I HDACs was ineffective.
Interestingly, a number of HDACis may be used to sensitize NSCLC cells to different death stimuli Figure 5 Small interference RNA (siRNA) against AIF prevents TSA/VP16-induced PARP cleavage and provides a marked protection against cell death in H157 cells. H157 cells were transiently co-transfected, using the nucleofector device, with plasmid encoding enhanced green fluorescence protein (EGFP) together with siRNA designed to interfere with the expression of human AIF. As control, siRNA directed against enhanced cyan fluorescent protein (ECFP) was used. Twenty-four hours post transfection, cells were treated with VP16, TSA or in combination and incubated for additional 24 h. (a) Total protein cell extracts were analysed by immunoblotting for the presence of AIF protein, 116 kDa native PARP and its 89 kDa caspase-3-cleavage product. Actin was used as protein loading standard. (b) Confocal analysis of AIF subcellular localization was performed by immunofluorescence using a polyclonal anti-AIF antibody revealed by an Alexa594-conjugated anti-rabbit antibody. Nuclei were counterstained with DAPI. EGFP was used as transfection marker. Confocal images of EGFP (green), immunostaining with AIF (red) antibodies and nuclear DAPI staining (blue) of H157 cells after TSA/VP16 treatment is depicted. The pink color in the merge is the result of an overlay between the red (AIF) and blue (nucleus) fluorescence determining the nuclear localization of AIF. These experiments were performed three times with similar results. (c) Apoptosis was assayed by scoring of EGFP expressing cells presenting condensed/fragmented nuclei. This experiment was repeated three times with similar results. Bars and error bars represent mean with s.e.m.
N Hajji et al (Rundall et al., 2005; Geng et al., 2006; Schniewind et al., 2006; Witta et al., 2006) . Nevertheless, the precise underlying mechanisms behind the cell death-promoting or -restoring effects of HDACis are unclear. Pharmacological experiments with zVAD-fmk revealed that caspases are required for TSA/VP16-induced cell death in NSCLC cells. Importantly, TSA/VP16-induced DCm loss as well as AIF release from the mitochondria and DNA fragmentation was inhibited by zVAD-fmk.
Several studies have advocated the idea that AIF is indeed a caspase-dependent death effector in certain models, meaning that the translocation of AIF from the mitochondrion to the nucleus would be caspase-dependent (Cande et al., 2004 ). It appears that, in several cell types, cytotoxic drug-and UV radiation-induced apoptosis relies on a caspase-mediated amplification loop for full activation of the mitochondrial apoptosis pathway ( Cells were harvested and total protein cell extracts were analysed by immunoblotting for the presence of Bcl-2 and Bcl-xL protein (both 26 kDa). G3PDH was used as protein loading standard. (d) H157 cells were transiently transfected using the nucleofector device with plasmid encoding Bcl-xL or the corresponding empty vector as control. Total protein cell extracts were analysed by immunoblotting for the presence of Bcl-xL protein, 116 kDa native PARP and its 89 kDa caspase-3-cleavage product. G3PDH was used as protein loading standard. (e) H157 cells were transfected with plasmid encoding Bcl-xL as in (a). Twenty-four hours post transfection, cells were treated with VP16, TSA or in combination and incubated for 24 h and then processed for immunofluorescence assay. The activated membrane-bound form of Bax was detected with the same polyclonal anti-Bax antibody as in the first panel (Alexa594). Overexpressed Bcl-xL was detected by immunofluorescence using the anti-Bcl-xL antibody and Alexa594-conjugated secondary antibody. Confocal images of immunostaining with active Bax (green) and Bcl-xL (red) antibodies and nuclear DAPI staining (blue) of H157 cells after TSA/VP16 treatment is depicted. For each panel, three independent experiments were performed yielding similar results.
TSA/VP16 induces apoptosis in NSCLC cells N Hajji et al necessity of caspases for AIF release distinguishes TSA/ VP16-mediated from, for example, STS-induced cell death. Indeed, we previously reported that inhibition of caspases failed to prevent the STS-induced mitochondrion-nuclear translocation of AIF and subsequent cell death in NSCLC cells (Joseph et al., 2002; Gallego et al., 2004) . Hence, in NSCLC cells, AIF can be released from mitochondria in a caspase-dependent as well as -independent manner. Caspase-dependent and -independent death effectors such as AIF may mediate apoptosis to a variable extent, depending on cellular context as well as the death-inducing stimulus.
Our results reveal that the co-treatment TSA/VP16 exerts its pro-apoptotic effect on the mitochondrial AIFdependent apoptotic pathways. As mentioned above, mitochondrial outer-membrane permeabilization, which is associated with AIF release in NSCLC cells (Joseph et al., 2002; Gallego et al., 2004) is controlled by the proand anti-apoptotic members of the Bcl-2 family (Desagher and Martinou, 2000; Shimizu et al., 2000) . It appeared that in NSCLC cells, TSA/VP16 cotreatment leads to a reduction in Bcl-xL expression, which allows the activation of Bax and the subsequent initiation of the AIF-dependent apoptotic pathway. Cell death in response to stimuli that require the activation of Bax to induce mitochondrial membrane permeabilization can be prevented upstream of Bax activation by the overexpression of the anti-apoptotic Bcl-xL proteins (Letai et al., 2002) . Altogether, our results show that the downregulation of Bcl-xL is required for the deathpromoting effect observed upon pan-HDAC inhibition.
In conclusion, in the NSCLC cell type where the Cyt c/caspase-dependent pathway is less efficient in inducing cell death, chemical inhibition of HDACs by TSA in association with exposure to the topoisomerase II inhibitor VP16 results in activation of an AIF-mediated caspase-dependent pathway, which circumvents the resistance observed upon treatment with conventional cytotoxic drugs and ionizing radiation (Figure 7) . The reduction of Bcl-xL expression in NSCLC cells by TSA sensitizes these cells to DNA damage-induced Bax activation upstream of DCm perturbation, and induction of the AIF death pathway. Interestingly, a Bcl-2/ Bcl-xL bispecific antisense oligonucleotide has been reported to promote apoptotic cell death in lung cancer cells (Zangemeister-Wittke et al., 2000) . In addition, BclxL overexpression has been shown to indicate poor prognosis for several human cancer, including in NSCLC patients (Karczmarek-Borowska et al., 2006) . These observations together with our present study suggest that pan-HDACi's such as TSA deserve attention as therapeutic compounds in NSCLC cancer and other malignancies in which Bcl-xL is overexpressed.
Materials and methods
Cell culture and treatments Etoposide (VP16) was from Bristol-Myers (New York, NY, USA). Trichostatin A (TSA) and 2-propylpentanoic acid, valproic acid (VPA) were purchased from Sigma (Stockholm, Sweden). Human NSCLC H157 cells were cultured at 37 1C, 5% CO 2 in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, penicillin (100U ml
À1
) and streptomycin (100 mg ml À1 ). Twenty-four hours after setting in culture dishes with fresh medium, cells were treated with 5 mM VP16, 1 mM VPA, 20ng ml À1 TSA alone or in combination. N-Benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone (zVAD-fmk; Bachem (Budendorf, Switzerland), 20 mM) was added 1 h before treatment. The cell density was kept at levels allowing exponential growth.
FACS analysis
Appearance of subdiploid-fragmented nuclei derived from apoptotic cells were analysed by FACS after DNA staining with 50 mg ml À1 propidium iodide in the presence of 0.5 mg ml À1 RNase A. Mitochondrial membrane depolarization was assessed by uptake of TMRE (25 nM; Molecular Probes, Carlsbad, CA, USA), a lipophilic, cationic fluorochrome dye that is only taken up by mitochondria having an intact electrochemical gradient. Analysis was carried out on a FACSCalibur flow cytometer equipped with CellQuest software (Becton Dickinson, San Jose, CA, USA).
Subcellular fractionation, immunoblotting analysis
Cytosolic and total protein extracts were made as reported in Rundall et al. (2005) . For immunoblot analysis, protein extracts were resolved on sodium dodecyl sulphate (SDS)-PAGE and blotted; protein pieces were detected with Figure 7 Death signaling pathways affected by TSA/VP16 co-treatment in NSCLC cells. VP16 and TSA/VP16 treatments both lead to the release of Cyt c and subsequent activation of caspases (a) but VP16 treatment alone fail to induce nuclear hallmarks of apoptosis in NSCLC cells. VP16 treatment alone is also unable to promote Bax activation, drop of DCm and engagement of the AIF-dependent death pathway (b). On the contrary, the combinatorial action of TSA and VP16, which provokes Bcl-xL expression downregulation, allows the activation of Bax and thereby activation of the AIF-dependent death pathway (2). Exposure to TSA/VP16 as well leads to caspase-3 translocation into the nucleus and the appearance of caspase-dependent nuclear events of apoptosis such as PARP processing. Caspase activity assay Activities of caspase-3-like enzymes were determined fluorometrically using DEVD-AMC, as substrate in a buffer containing 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 0.1% 3-((3-holamidopropyl) dimethylammonio) -1-propanesulfonic acid, CHAPS, 5 mM dithiothreitol, 10 À6 % Nonidet P-40 and 10% sucrose as previously described (Joseph et al., 2001 ).
Pulse-field gel electrophoresis Formation of high-molecular weight DNA fragments was determined by using field inversion gel electrophoresis, as previously described (Zhivotovsky et al., 1994) . DNA was stained with ethidium bromide, visualized using a 305 nm UV light source and photographed with BioRad Geldoc quantity program.
Immunofluorescence and confocal microscopy Antibodies raised against acetylated histone H4 (Upsate, Billerica, MA, USA), AIF (Santa Cruz Biotechnology, Santa Cruz, CA, USA), active Bax (clone 6A7, BD Pharmingen) and Bcl-xL (Dako) were used for immunodetection. AlexaFluor 488-or Alexa 594-conjugated anti-immunoglobulin G was used as secondary antibodies (Molecular Probes). Paraformaldehyde fixed cells were blocked in HEPES, 3% BSA, 0.3% Triton X-100 and incubated with primary (4 1C, overnight) and secondary antibodies (room temperature, 1 h). Cell nuclei were counterstained with DAPI (1 mg ml
À1
). Samples were mounted with 90% glycerol in phosphate-buffered saline and analysed under Zeiss 510 META confocal laser scanning microscopy (Zeiss) equipped with an inverted Zeiss Axiovert 200 microscope. Mix dyes were acquired by sequential multiple channel fluorescence scanning to avoid bleeds through. Routinely, 0.15-to 0.20-mm-thick focal planes were scanned. Chats were quantified and images were processed using the Zeiss Software.
Nucleofection siRNA designed to interfere with the expression of human AIF and CFP were purchased from Dharmacon (Walthman, MA, USA) and Eurogentech (Seraing, Belgium), respectively. Plasmid encoding Bcl-xL was a gift from Dr U Moll. pmaxGFP plasmid used as control was from Amaxa. Transient transfections were done using the Nucleofector device (Amaxa). In short, 2 Â 10 6 H157 cells were suspended in 100 ml Cell line Nucleofector solution T, 5 mg plasmid was added and the cells were electroporated (program A 23), resuspended in 2.5 ml prewarmed cell culture medium and transferred to a 37 1C incubator. The survival rate was measured by Trypan blue exclusion and found to be higher than 80%. Transfection efficiency was monitored by fluorescence using pmaxGFP plasmid of the Nucleofector kit. siRNA sequence for enhanced CFP: 5 0 -GGCCUUGAUGCCGUUC UUC99-3 0 , Eurogentech. siRNA AIF (human, PDC8 NM_004208), SMARTpool, cat no. M_001912 and siRNA Bcl-xL (human, BCL2L1 NM_001191), SMARTpool, cat no. L_003458 (Dharmacon).
Statistics
All experiments were performed at least three times with similar results. Bars and error bars represent mean with s.e.m.
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